**Management's Discussion and Analysis of Operations**
**For the years ended September 30, 2014 and December 31, 2013**

*This Management's Discussion and Analysis ("MD&A) is prepared as January 28, 2015 and has been prepared in accordance with International Financial Reporting Standards ("IFRS). All amounts are in Canadian dollars.*

*Management is responsible for the preparation and integrity of the financial statements, including the maintenance of appropriate information systems, procedures and internal controls and to ensure that information used internally or disclosed externally, including the financial statements and MD&A, is complete and reliable. The Company's directors follows recommended corporate governance guidelines for public companies to ensure transparency and accountability to shareholders. The board's audit committee meet with management quarterly to review the financial statements including the MD&A and to discuss other financial, operating and internal control matters.*

***Caution Regarding Forward Looking Statements***

*This document contains forward looking statements, such as statements regarding future sales opportunities in various global regions and financing initiatives that are based on current expectations of management. These statements involve uncertainties and risks, including Monarch Energy Limited's (Monarch or the Company) ability to obtain and/or access additional financing with acceptable terms, and delays in anticipated product sales. Such forward-looking statements should be given careful consideration and undue reliance should not be placed on these statements.*

*The preparation of Management's Discussion and Analysis (MD&A) may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Management bases estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Management believes the accounting policies, outlined in the Significant Accounting Policies section of its consolidated financial statements, affect its more significant judgments and estimates used in the preparation of its consolidated financial statements.*

## Introduction

The following MD&A for the years ended September 30, 2014 and December 31, 2013 has been prepared to help investors understand the financial performance of Monarch in the broader context of the Company's strategic direction, the risk and opportunities as understood by management, and the key metrics that are relevant to the Company's performance. The Audit Committee of the Board of Directors has reviewed this document and all other publicly reported financial information for integrity, usefulness, reliability and consistency.

All amounts are expressed in Canadian dollars (CAD) unless otherwise noted.

Additional information about ChroMedX Corp. (formerly Monarch Energy Limited ("Monarch")) ("the Company" or "ChromedX Corp"), this document, and the related quarterly financial statements can be viewed on the Company's website at www.chromedX.com and are available on SEDAR at www.sedar.com.

The financial reporting periods of Monarch were the reporting periods of ChroMedX which had a December 31 year end. Monarch has decided to change its year end to September 30 to coincide with the year end of the reporting issuer prior to completion of the Transaction. As such, the first financial year end for ChroMedX following the Transaction will be September 30, 2014, being the transition year.

The Company's Common Shares are listed and traded on the CSE ("CSE") under the symbol CHX.

**Results of operation**

On June 30, 2014, the Company completed a transaction which resulted in the acquisition of ChroMedX, a company incorporated under the laws of Ontario on December 3, 2013. As the former ChroMedX shareholders ended up owing the majority of the Company upon completion of the transaction, the transaction was deemed to be a reverse takeover.

The share capital of Monarch and ChroMedx was as follows immediately prior to the transaction:

| | Monarch | ChroMedX | Adjustments related to the RTO | Combined |
|---|---|---|---|---|
| Common shares | 101,851,860 | 9,675,100 | (96,759,267) | 14,767,693 |
| Dollars | $ 19,466,341 | $ 607,501 | $ (18,951,887) | $ 1,121,955 |
| Shares issued for patent transfer | - | 15,000,000 | - | 15,000,000 |
| Dollars | $ - | $ 1,515,300 | $ - | $ 1,515,300 |

In accordance with IFRS 3, Business Combination, the substance of the transaction is a reverse takeover of a non-operating company. The transaction does not constitute a business combination as the Company does not meet the definition of a business under the standard. As a result, the transaction is accounted for as an acquisition of a stock exchange listing with ChroMedX being identified as the acquirer and the equity consideration being measured at fair value.

The cost of the transaction was calculated as follows:

| | | |
|---|---|---|
| 5,092,593 common shares acquired (1:20 consolidation) | $ | 514,455 |
| Other net liabilities assumed | | 185,936 |
| Transaction costs | | 45,626 |
| | $ | 746,017 |

Chromedx Ltd. ("ChroMedX" or the "Company") is a 100% owned subsidiary of ChroMedX Corp.

ChroMedX, following the acquisition of the Patents (as defined and described below from Invidx Corp. ("Invidx") (formerly ChroMedX Inc.), is developing novel medical devices for Point of Care Testing (POCT), blood sample collection, and serum/plasma treatment and analysis. Based on previous devices and numerous patents, both issued and applied for, developed by Dr. James Samsoondar, a clinical biochemist, the devices represent disruptive technologies for the POCT and In Vitro Diagnostic (IVD) market.

The Company will have two platform technologies. The initial platform will focus on devices and methodologies for blood sample collection and analysis. The analysis of the oxygen carrying state of hemoglobin in the blood is known as CO-oximetry. It is a critical measurement of a patient's condition. As well as determining if there is oxygen deficiency at the tissue level CO-oximetry determines the degree of any carbon monoxide poisoning (carboxy-hemoglobin) that may be affecting the patient. In addition, measurement of methemoglobin will indicate if a patient has been exposed to certain environmental toxins containing nitrates and is also used to monitor certain neonatal treatments. Thus rapid analysis of hemoglobin status and blood oxygenation as well as acid/base balance and electrolyte levels is an essential tool for patient evaluation. This information is of particular importance for first responder patient evaluation and in emergency and operating rooms in healthcare facilities. A hand-held device for measuring CO-oximetry, blood gases (including pH) and electrolytes represents the initial projects based upon the first technology platform. Additional devices based on the same platform will provide innovative measurement techniques for neonatal bilirubin analysis and other blood chemistry markers.

The second technology platform is based on ultrafiltration and will be applied to several applications. The first will provide plasma separation from whole blood during blood collection which avoids the step of centrifugation in the laboratory. The second application will process plasma to remove proteins in preparation for analysis. The Company's plasma/serum ultrafiltration technology will provide the next innovation in measurement of free hormones and therapeutic drugs using existing laboratory immunoanalysers, but with reduced sample preparation time and cost. Proof of concept for this technology has been demonstrated.

The Company will develop its technologies in collaboration with major hospitals and universities and will seek strategic relationships with existing medical diagnostic companies, as well as companies that desire to enter into the field of medical diagnostics.

ChroMedX Ltd. is led by an experienced management team, all of whom have advanced technical training and past start-up experience. A full suite of patents has been developed and these have either been granted by the USPTO or have been filed. Appropriate PCT filings for the patents are being executed, which enable worldwide protection of the ChroMedX's intellectual property.

**Selected quarterly Information**

The following table sets forth selected financial information for Chromedx Corp. for the year ended September 30, 2014 and ChroMedX Ltd. for the year ended ended December 31, 2013. This information has been derived from Company's financial statements for the years and should be read in conjunction with financial statement and the notes thereto.

| | **For the year ended September 30, 2014** | **For the year ended December 31, 2013** |
|---|---|---|
| Income | nil | nil |
| Expenses | $1,653,138 | $410 |
| (Loss) for the year | $(1,653,138) | $(410) |
| Loss per share | $(0.13) | $(4.10) |
| Total assets | $1,947,364 | $27,591 |
| Total Liabilities | $161,391 | nil |
| Working capital | $309,117 | $11,591 |

Per share amounts are calculated using the weighted have not been calculated, as they would be anti-dilutive.
average number of shares outstanding. Fully diluted loss per share amounts

**Revenue and Expenses**

**For the year ending September 30, 2014.**

The net (loss) for the year ending September 30, 2014 was ($1,653,138)($0.13/share).

Consulting fees were $321,942 due to the hiring of a management team, including the President (under management fees of $125,800) Chief Financial Officer and necessary administrative staff along with numerous outside consultants. Administration expenses were $107,014, mainly due to first year startup costs. The largest expense for the quarter was the RTO listing expense of $746,017; this expense was calculated as follows:

| | | |
|---|---|---|
| 5,092,593 common shares acquired (1:20 consolidation) | $ | 514,455 |
| Other net liabilities assumed | | 185,936 |
| Transaction costs | | 45,626 |
| | $ | 746,017 |

**Summary of Quarterly Results**

The following table is a summary of selected unaudited financial information for the three most recent fiscal quarters. Since the Company was incorporated December 3, 2013, there are only three reporting periods

| Quarter ended | Income | Net income (loss) | Net income (loss) per share |
|---|---|---|---|
| September 30, 2014 | Nil | $ (756,588) | $ (0.14) |
| June 30, 2014 | Nil | $ (880,100) | $ (5.32) |
| March 31, 2014 | Nil | $ (16,450) | $ (164.50) |
| December 31, 2013 | Nil | $ (410) | $ (4.10) |
| | | | |
| | | | |
| *IFRS reporting | | | Fully diluted loss per share amounts are not shown as they would be anti-dilutive. |

There can be significant variances in Company's reported loss from quarter to quarter arising from factors that are difficult to anticipate in advance or to predict from past results.

**Liquidity**

The majority of financing of current operations is achieved by issuing share capital. At the year ending September 30, 2014, Company had cash of $323,231, HST receivable of $38,414, prepaid of $79,694 and amounts receivable of $315. The Company has accounts payable of $119,172 and due to related parties of $13,365. Company had a positive working capital of $309,117 at September 30, 2014.

In April 2014, the Company completed a private placement of 3,000,000 shares at a price of $0.02 per share for aggregate proceeds of $60,000.

In April 2014, the Company completed a second tranche private placement of 1,500,000 units at a price of $0.02 per unit for aggregate proceeds of $30,000. Each unit consists of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of $0.15 per a common share for a period of 18 months from the date the Company lists on a recognized Canadian Stock.

In June 2014, the Company completed a third tranche private placement of 5,175,000 units at a price of $0.10 per unit for aggregate proceeds of $517,500. Each unit consist of one common share of the Company and one-half common share purchase warrant with each warrant entitles the holder thereof to acquire one common share at a price of $0.15 per a common share for a period of 12 months the date the Company lists on a recognized Canadian Stock Exchange and one-half common share purchase warrant with each warrant entitles the holder thereof to acquire one common share at a price of $0.25 per a common share for a period of 24 months from the date the Company lists on a recognized Canadian Stock Exchange.

In June 2014, the Company issued 15,000,000 shares for Patents and Patents pending relating to the technology.

In September 2014, the Company completed a private placement of 6,145,000 units at a price of $0.10 per unit for aggregate proceeds of $614,500. Each unit consist of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of $0.25 per a common share for a period of 18 months from the date of issuance. In connection with this financing, the Company paid cash commissions of $10,000 and issued 100,000 broker warrants where each broker warrant entitles the holder to acquire one additional common share at a price of $0.10 for a period of 18 months from the date of issuance.

**Investing Activities**

The Company was involved in the acquisition of ChromedX, which ChromedX, as the acquirer, acquiring the net assets of Monarch Energy Limited during the year ended September 30, 2014.

**Off-Balance Sheet Arrangements**

The Company has not entered into any off balance sheet arrangements, other than previously disclosed, that has, or is reasonably likely to have, an impact on the current or future results of operations or the financial condition of our company.

**Transactions with Related Parties**

Related parties and related party transactions impacting the accompanying financial statements are summarized below and include transactions with the following individuals or entities:

The Company purchased a patent option from InvidX Corp, a company controlled by an officer of the Company, on June 16, 2014 and exercised the option on December 9, 2014 (Note 5)

As at September 30, 2014, the Company had $5,000 due from officers and directors of the Company and $13,365 due to officers and directors of the Company. In addition, the Company paid $239,100 management fees to directors.

*Key management personnel*:

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Company's Board of Directors and corporate officers.

Remuneration attributed to key management personnel can be summarized as follows:

| | **September 30, 2014** | December 31, 2013 |
|---|---|---|
| | | $ - |
| Stock Based Compensation (Note 7 (b)) | $ 197,765 | |
| Short-term benefits* | $ 236,100 | $ - |

*includes base salaries pursuant to contractual employment, or consultancy arrangements. These have been recorded in consulting fees and management fees.

**Events After Year End**

October 6, 2014, the Company issued 600,000 incentive options to officers, directors, consultants and employees. The options have a strike price of $0.18 and expire October 6, 2017.

November 28, 2014, the Company issued an additional 550,000 incentive options to officers, directors, consultants and employees. The options have a strike price of $0.345 and expire November 28, 2019.

**International Financial Reporting Standards ("IFRS")**

In February 2008, the Canadian Accounting Standards Board confirmed that Canadian generally accepted accounting principles (GAAP), as used by publicly accountable enterprises, would be fully converged into IFRS, as issued by the International Accounting Standards Board (IASB), effective for fiscal years beginning on or after January 1, 2011. The Company implemented for the years ended September 30, 2014 and the year ended December 31, 2013.

The Company is in the process of adapting its business processes, financial systems, accounting policies, disclosure controls and procedures and internal controls over financial reporting to IFRS. No material change in business processes, financial systems, disclosure controls and procedures and internal controls over financial reporting is expected to result from the adoption and implementation of IFRS.

**Critical Accounting Policies and Estimates**

Going concern

These unaudited interim financial statements have been prepared in accordance with IFRS 1 and IAS 34 on a going concern basis which assumes that Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. Company has incurred losses from inception and the inability to raise additional financing may impact the future assessment of Company as a going concern. Company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. While Company has been successful in obtaining its required financing in the past, there is no assurance that such financing will be available in the future. These financial statements do not include any adjustments to the amounts and classification of asset's and liabilities that might be necessary should Company not be able to continue as a going concern.

Significant accounting judgments and estimates

The preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant areas requiring the use of management estimates relate to the determination of carrying value of resource properties, warrants, stock-based compensation, and deferred tax assets and liabilities. Financial results as determined by actual events could differ from those estimates.

**Risks and Uncertainties**

*History of Losses* – The Company has been in a cumulative net loss position throughout its operating history. The Company's limited operating history makes it difficult to evaluate the future financial prospects of its business. There is no assurance that the Company will grow or be profitable or that the Company will have earnings or significant improvement in its cash flow from operations in the future. The future earnings on and cash flow from operations are dependent on the Company's ability to further develop and sell its products and the Company's operational expenses. Management expects that the Company will continue to have high levels of operating expenses, since the Company needs to make significant up-front expenditures for product development, and corporate development activities. Management anticipates that the operating losses for the Company may continue until such time as the Company consistently generates sufficient revenues to support operations.

*Need for Additional Financing* - The implementation of the Company's business plan requires significant capital outlays and operating expenditures over the next several years. There can be no assurance that additional financing will be available to the Company when needed, on commercially reasonable terms, or at all. Any inability to obtain additional financing when needed would have a material adverse effect on the Company. Further, any additional equity financing may involve substantial dilution to the Company's then existing shareholders. Debt financing, if available, may involve onerous obligations, monetary or otherwise. If adequate funds are not available, the Company may obtain funds through arrangements with strategic partners or others who may require the Company to relinquish rights to certain technologies, any of which could adversely affect its business, financial condition and results of operations.

*Product Risks*

*Uncertain Demand for Products* - Demand for medical technologies is dependent on a number of social, political and economic factors that are beyond the control of the Company. The healthcare industry is likely to continue to change as the public, government, medical practitioners, and the medical industries focus on ways to expand medical coverage while controlling the growth in healthcare costs. While the Company believes that demand for medical technologies will continue to grow, there is no assurance that such demand will exist or that the Companies products will be purchased to satisfy that demand.

*Dependence on Development of New Products* - New technological or product developments in the medical industry may render the Company's products obsolete or reduce their value. The Company's future prospects are highly dependent on its ability to develop new products - from new technologies and achieve market acceptance. There can be no assurance that the Company will be successful in these efforts.

**Disclosure Controls and Procedures & Internal Controls over Financial Reporting**

In accordance with the Canadian Securities Administrators National Instrument 52-109 ("NI 52-109"), Certification of Disclosure in Issuers' Annual and Interim Filings, the Company has filed certificates signed by the Chief Executive Officer and the Chief Financial Officer that, among other things, report on the design and effectiveness of disclosure controls and procedures and the design and effectiveness of internal controls over financial reporting.

The Company continues to review and document its disclosure controls and procedures and internal controls over financial reporting and may, from time to time, make changes aimed at enhancing their effectiveness and to ensure that its systems evolve with the business. There were no changes in the Company's internal controls over financial reporting during the year ended September 30, 2014 that have materially affected, or are reasonably likely to materially affect, its disclosure controls and procedures and internal controls over financial reporting.

**Share Data**

The following sets forth the outstanding securities of Company as at September 30, 2014:

The authorized capital of Company consists of an unlimited number of common shares

*Common Shares and warrants–*

During the period Monarch consolidated their shares on a 1:20 basis leaving 5,092,593 shares

In April 2014, the Company completed a private placement of 3,000,000 shares at a price of $0.02 per share for aggregate proceeds of $60,000.

In April 2014, the Company completed a second tranche private placement of 1,500,000 units at a price of $0.02 per unit for aggregate proceeds of $30,000. Each unit consist of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of $0.15 per a common share for a period of 18 months from the date the Company lists on a recognized Canadian Stock Exchange.

In June 2014, the Company completed a third tranche private placement of 5,175,000 units at a price of $0.10 per unit for aggregate proceeds of $517,500. Each unit consist of one common share of the Company and one-half common share purchase warrant with each warrant entitles the holder thereof to acquire one common share at a price of $0.15 per a common share for a period of 12 months from the date the Company lists on a recognized Canadian Stock Exchange and one-half common share purchase warrant with each warrant entitles the holder thereof to acquire one common share at a price of $0.25 per a common share for a period of 24 months from date the Company lists on a recognized Canadian Stock Exchange.

In June 2014, the Company issued 15,000,000 shares for Patents and Patents pending relating to the technology.

In September 2014, the Company completed a private placement of 6,145,000 units at a price of $0.10 per unit for aggregate proceeds of $614,500. Each unit consist of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of $0.25 per a common share for a period of 18 months from the date of issuance. In connection with this financing, the Company paid cash commissions of $10,000 and issued 100,000 broker warrants where each broker warrant entitles the holder to acquire one additional common share at a price of $0.10 for a period of 18 months from date of issuance.

As of September 30, 2014 there are 35,912,693 shares issued and outstanding and 12,920,000 warrants.

*Options* – During the period, the Company issued 2,950,000 incentive options to officers, directors, consultants and employees. The options have a strike price of $0.10 and expire July 10, 2019.

As of January 28, 2015 the Company had 42,874,644 common shares, 12,920,000 warrants and 3,900,000 options outstanding.

Signed

*"Wayne Maddever"*
CEO
January 28, 2015